Altimmune, Inc. (ALT)

NGM – Real vaqt narxi. Valyuta: USD

3.08

-0.01 (-0.32%)

Yopilishda: May 12, 2026, 4:00 PM EDT

3.14

+0.06 (1.94%)

Bozor oldidan: May 13, 2026, 5:47 AM EDT

06.05.2026

Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

GAITHERSBURG, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its first quarter 2026 financial results on Wednesday, May 13, 2026.

27.04.2026

Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities

$225 million funded at closing, with an additional $225 million warrant tranche Financing funds operations through anticipated Phase 3 MASH 52-week data readout Financing was led by Deep Track Capital, with participation from TCGX, Viking Global Investors, RA Capital Management, and other new and existing investors GAITHERSBURG, Md., April 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced the closing of its previously announced underwritten public offering consisting of (i) 64,250,000 shares of its common stock and 64,250,000 accompanying common stock warrants to purchase shares of common stock or pre-funded warrants in lieu thereof and (ii) in lieu of common stock, to certain investors that so choose, pre-funded warrants to purchase an aggregate of up to 10,750,000 shares of its common stock and 10,750,000 accompanying common stock warrants to purchase shares of common stock or pre-funded warrants in lieu thereof, each at an exercise price of $0.001 per pre-funded warrant.

23.04.2026

Altimmune Catalysts: 2026 Data Readouts and Financing Risks

ALT's 2026 hinges on pemvidutide, with key readouts, a phase III start, and funding strategy set to shape investor sentiment.

23.04.2026

ALT Stock: What Pemvidutide Means for MASH, AUD and ALD

Altimmune bets big on pemvidutide across MASH, AUD and ALD, but with one drug driving value, upcoming trials could make or break the story.

23.04.2026

Is Altimmune a Buy Before Phase III MASH Starts in 2026?

ALT heads into a high-stakes 2026 as pemvidutide drives key phase III and mid-stage catalysts that could reshape its valuation-or risk setbacks.

23.04.2026

Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities

GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced the pricing of its previously announced underwritten public offering consisting of (i) 64,250,000 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 64,250,000 shares of common stock (or pre-funded warrants in lieu thereof) and (ii) in lieu of common stock, to certain investors that so choose, pre-funded warrants to purchase an aggregate of up to 10,750,000 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 10,750,000 shares of common stock (or pre-funded warrants in lieu thereof), at an exercise price of $0.001 per pre-funded warrant. The common stock and pre-funded warrants are being sold in combination with an accompanying common stock warrant to purchase one share of common stock (or pre-funded warrant in lieu thereof) issued for each share of common stock or pre-funded warrant sold. The accompanying common stock warrant has an exercise price of $3.00 per share, is immediately exercisable from the date of issuance and will expire upon the earlier of (i) the fifth anniversary of the original issuance date and (ii) forty-five days following the Company's public announcement of a successful data readout of its Phase 3 trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (“MASH”). The combined offering price of each share of common stock and accompany common stock warrant is $3.00. The combined offering price of each pre-funded warrant and accompanying common stock warrant is $2.999. The offering is expected to close on or about April 24, 2026, subject to satisfaction of customary closing conditions.

22.04.2026

Altimmune Announces Proposed Underwritten Public Offering of Securities

GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced it has commenced an underwritten public offering of shares of its common stock and accompanying common stock warrants to purchase an equivalent number of shares of its common stock (or pre-funded warrants in lieu thereof), and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock and accompanying common stock warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof). All of the shares, pre-funded warrants and accompanying common stock warrants to be sold in the proposed public offering are being offered by Altimmune. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed public offering may be completed or as to the actual terms of the offering.

Videolar

No Data

There is no data to display

Press-relizlar

27.04.2026

Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities

23.04.2026

Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities

22.04.2026

Altimmune Announces Proposed Underwritten Public Offering of Securities

GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced it has commenced an underwritten public offering of shares of its common stock and accompanying common stock warrants to purchase an equivalent number of shares of its common stock (or pre-funded warrants in lieu thereof), and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock and accompanying common stock warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof). All of the shares, pre-funded warrants and accompanying common stock warrants to be sold in the proposed public offering are being offered by Altimmune. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed public offering may be completed or as to the actual terms of the offering.

05.03.2026

Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates

Initiation of Phase 3 MASH trial planned for 2026 Pemvidutide granted FDA Breakthrough Therapy Designation in MASH Topline data from RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder (AUD) expected in third quarter 2026 Cash, cash equivalents and short-term investments of $274 million as of December 31, 2025; Balance sheet further strengthened through $75 million registered direct offering in January 2026 Webcast to be held today, March 5, 2026, at 8:30 a.m. ET GAITHERSBURG, Md.

Altimmune, Inc. (ALT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Altimmune, Inc. (ALT)

Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities

Altimmune Catalysts: 2026 Data Readouts and Financing Risks

ALT Stock: What Pemvidutide Means for MASH, AUD and ALD

Is Altimmune a Buy Before Phase III MASH Starts in 2026?

Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities

Altimmune Announces Proposed Underwritten Public Offering of Securities

Videolar

No Data

Press-relizlar

Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities

Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities

Altimmune Announces Proposed Underwritten Public Offering of Securities

Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates

Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities

Altimmune Catalysts: 2026 Data Readouts and Financing Risks

ALT Stock: What Pemvidutide Means for MASH, AUD and ALD

Is Altimmune a Buy Before Phase III MASH Starts in 2026?

Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities

Altimmune Announces Proposed Underwritten Public Offering of Securities

Videolar

No Data

Press-relizlar

Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities

Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities

Altimmune Announces Proposed Underwritten Public Offering of Securities

Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates

Search stocks

Altimmune, Inc. (ALT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Altimmune, Inc. (ALT)

Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities

Altimmune Catalysts: 2026 Data Readouts and Financing Risks

ALT Stock: What Pemvidutide Means for MASH, AUD and ALD

Is Altimmune a Buy Before Phase III MASH Starts in 2026?

Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities

Altimmune Announces Proposed Underwritten Public Offering of Securities

Videolar

No Data

Press-relizlar

Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities

Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities

Altimmune Announces Proposed Underwritten Public Offering of Securities

Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates

Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities

Altimmune Catalysts: 2026 Data Readouts and Financing Risks

ALT Stock: What Pemvidutide Means for MASH, AUD and ALD

Is Altimmune a Buy Before Phase III MASH Starts in 2026?

Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities

Altimmune Announces Proposed Underwritten Public Offering of Securities

Videolar

No Data

Press-relizlar

Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities

Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities

Altimmune Announces Proposed Underwritten Public Offering of Securities

Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates